Lumea, a leader in digital pathology solutions. AIRA Matrix Private Limited, an innovative technology company for AI-based diagnostic, prognostic, and predictive applications in cancer care. Acupath, a leading provider of sub-specialized anatomic and molecular pathology services. These companies have joined forces to deliver an AI-based solution to assist in the diagnosis of urinary bladder cancers through cytopathological examination.
This joint effort ensures the availability of AI solutions that improve the accuracy and turnaround time of bladder cancer diagnosis by automating the quantification of the URO17® test. URO17®, an antibody that detects the presence of the novel biomarker Keratin 17 (K17), is a non-invasive immunocytochemical urine test that is used in conjunction with traditional urine cytology to assist in the diagnosis and management of bladder cancer.
"This collaboration represents a significant step forward in our mission to improve the standard of care through innovative AI solutions. By collaborating with Acupath, we aim to provide pathologists with powerful tools to make accurate diagnoses and help improve treatment decisions and patient outcomes," said Chaith Kondragunta, CEO of AIRA Matrix.
John Cucci, Chief Sales Officer of Acupath, emphasizing the potential of this partnership, said, "The URO17 bladder cancer biomarker has 6 years of proven clinical utility, numerous peer-reviewed published papers, and significant financial upside for labs. The addition of this innovative algorithm helps deliver the best possible quality and patient care while materially improving the workflow efficiency related to case sign out. Acupath appreciates the opportunity to collaborate with cutting-edge companies like AIRA Matrix and Lumea."
"We are excited about this collaboration and the development of an innovative algorithm that will enhance diagnostics and, ultimately, improve patient care. By partnering with leading artificial intelligence developers and cutting-edge pathology laboratories, Lumea continues to deliver the most advanced digital platform and workflow solutions," Said James Thackeray, Lumea's Chief Commercial Officer.
Together, this partnership aims to advance pathology diagnostics and deliver high-quality patient care through digital solutions.